CTOs on the Move

Avamere

www.avamere.com

 
Avamere Family of Companies, a group of independent privately owned post-acute care companies, is dedicated to seniors` health and well-being. We take great pride in offering a continuum of care, which allows seniors to stay independent and active.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.avamere.com
  • 25115 SW Parkway Ave Suite B
    Wilsonville, OR USA 97070
  • Phone: 877.282.6373

Executives

Name Title Contact Details

Similar Companies

SCP Health

SCP Health (SCP) is a clinical company. At our core we work to bring hospitals and healers together in the pursuit of clinical effectiveness. With a portfolio of over 8 million patients, 7500 providers, 30 states, and 400 healthcare facilities, SCP Health is a leader in clinical practice management spanning the entire continuum of care, including emergency medicine, hospital medicine, wellness, telemedicine, intensive care, and ambulatory care. Whether you`re a resident, nurse practitioner, physician assistant, physician, or medical director looking for a clinical career or a professional interested in opportunities at one of our corporate locations, we can find you a position that fits you professionally and personally.

Synergetics USA, Inc

Synergetics USA, Inc. (Synergetics USA) designs, manufactures and markets microsurgical instruments, medical capital equipment and other medical devices primarily for use in ophthalmic surgery and neurosurgical applications.

Pyx Health

Pyx Health is leading the solution to Loneliness and Social Isolation through technology and human connection.

CSI Medical Education

CSI Medical Education is a Madison, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.